Web Exclusives

The Final Rule by the HSS means that manufacturers’ copay cards or coupons do not apply to a patient’s deductible or out-of-pocket maximum limits in certain situations, but further clarification is needed. Read More ›

CMS approves changes allowing limited utilization management in protected classes of drugs. However, other proposed changes that would have further eroded patient access were not implemented. Read More ›

A bipartisan bill designed to remove disparity in pricing between intravenously administered drugs and orally administered drugs for patients with cancer was passed in the House in March 2019 but awaits action in the Senate. Read More ›

There are important changes to beneficiaries’ Medicare Part D prescription drug coverage for 2020. These changes will affect many patients’ out-of-pocket spending for anticancer drugs, including poly (ADP-ribose) polymerase inhibitors. Read More ›

The American Cancer Society reports good news regarding the overall lower rate of cancer-related mortalities in the United States, but also points to some disturbing trends. Read More ›

The FDA approval of avapritinib marks the first time a drug has been approved specifically for patients with GIST harboring PDGFRA exon 18 mutations, which are involved in approximately 10% of GIST cases. Read More ›

The FDA has confirmed another strong year regarding the approval of innovative new drugs and biosimilars, including several agents used in the treatment of patients with cancer. Read More ›

Pancreatic cancer is a difficult to treat malignancy with a high mortality rate. Patients are usually diagnosed with advanced disease, and many are not eligible for surgery. Although systemic therapy is a mainstay of treatment, there are limited options for patients with metastatic disease. We invite you to read more about some of the recent observational data on metastatic pancreatic cancer treatment patterns, patient outcomes, and costs in an effort to shed insights into real-world clinical decisions and the economic factors that influence them. Read More ›

• Brukinsa Receives Accelerated FDA Approval for Mantle-Cell Lymphoma
• Ziextenzo Third Biosimilar to Neulasta Approved for Febrile Neutropenia
• Tecentriq Approved with Chemotherapy for First-Line Treatment of Metastatic NSCLC without EGFR or ALK Mutations
• FDA Approves Calquence for Adults with CLL or SL
• Zejula Receives FDA Approval for HRD-Positive Advanced Ovarian Cancer

Read More ›

On December 12, 2019, the FDA issued draft guidance to implement amendments to the Federal Food, Drug, and Cosmetic (FD&C) Act that will facilitate early assessment of studies of molecularly targeted oncology drugs that may be effective in the treatment of pediatric cancers. Read More ›